VivoSeq
Oncology

Lymphoid Leukemia

32

Pipeline Programs↗

3

Active Trials↗

21

Companies Involved↗

Lymphoid Leukemia is a moderately active landscape with 32 programs across 21 companies. The most active players are Institut de Recherches Internationales Servier, Traws Pharma, Inc., Eli Lilly. 14 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

0/100

Mech. Concentration

15/100

Completion Rate

67/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier

1 program

Phase 1T

Traws Pharma, Inc.

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1D

Dutch Childhood Oncology Group

1 program

Phase 2G

Genzyme, a Sanofi Company

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

71%

Small molecule

22 of 31 classified programs — the dominant modality here.

29%ALL OTHERSMonoclonal antibody413%Protein / enzyme413%Cell therapy13%

Small molecule leads; the ring shows all 31 classified programs, each share of the total. Modality classified for 100% of 32 pipeline programs.

Analysis

Trial Status

7

clinical trials

Active, not recruiting3 · 43%
Completed2 · 29%
Unknown status1 · 14%
Terminated1 · 14%

Clinical Trials

Trial Activity

7 trials

Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy
Active, not recruiting·—·Phase 2·NCT04778579·50 enrolled
Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A
Active, not recruiting·FFrench Innovative Leukemia Organisation·Phase 2·NCT03766763·82 enrolled
A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19
Active, not recruiting·Institut de Recherches Internationales Servier logoInstitut de Recherches Internationales Servier·Phase 1·NCT02735083·28 enrolled
Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL)
Completed·Mmedac GmbH·Phase 2·NCT00983138·12 enrolled
Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia
Completed·National Cancer Institute (NCI)·Phase 1/2·NCT00001575·87 enrolled
Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia
Terminated·TTraws Pharma, Inc.·Phase 1·NCT01049113·7 enrolled
My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia
Unknown status·UUniversity of Bologna·Phase 2·NCT00801580·3 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)